Inhibrx Net Income From Continuing Ops from 2010 to 2025

INBX Stock  USD 13.39  0.25  1.90%   
Inhibrx Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2025. During the period from 2010 to 2025, Inhibrx Net Loss regression line of annual values had r-squared of  0.75 and arithmetic mean of (67,623,148). View All Fundamentals
 
Net Loss  
First Reported
2019-06-30
Previous Quarter
1.9 B
Current Value
-43.9 M
Quarterly Volatility
403.9 M
 
Covid
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx's main balance sheet or income statement drivers, such as Interest Expense of 38.4 M, Minority Interest of 0.0 or Tax Provision of 2.6 K, as well as many indicators such as Price To Sales Ratio of 940, Dividend Yield of 0.0021 or PTB Ratio of 38.9. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules.
  
Check out the analysis of Inhibrx Correlation against competitors.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

Latest Inhibrx's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Inhibrx over the last few years. It is Inhibrx's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Inhibrx Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(67,623,148)
Geometric Mean46,132,367
Coefficient Of Variation(92.24)
Mean Deviation52,146,309
Median(22,080,000)
Standard Deviation62,376,744
Sample Variance3890.9T
Range166.6M
R-Value(0.87)
Mean Square Error1026.7T
R-Squared0.75
Significance0.000013
Slope(11,374,564)
Total Sum of Squares58362.9T

Inhibrx Net Income From Continuing Ops History

2025-161.3 M
2024-169.8 M
2023-188.7 M
2022-145.2 M
2021-81.8 M
2020-76.1 M
2019-51.4 M

About Inhibrx Financial Statements

Inhibrx investors use historical fundamental indicators, such as Inhibrx's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-169.8 M-161.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.